LIVE
EDAP
EDAP TMS S.A. · Health Care - Medical Devices
$4.77
+14.66% this month
VERSUS
⟷
COMPARE
IRTC
iRhythm Technologies, Inc. · Health Care - Medical Devices
$104.65
-8.07% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
EDAP
3
IRTC
1
Comparison scoreboard
EDAP LEADS 3/5AI Score
EDAP ✓37.0
IRTC 34.5
1Y Return
EDAP ✓+169.49%
IRTC -28.09%
Fwd P/E
EDAP ✓-7.32
IRTC 99.54
Target Up.
EDAP +35.03%
IRTC ✓+70.98%
Op. Margin
EDAP N/A
IRTC N/A
Metrics last refreshed: 6/20/2026
Quick take
EDAP vs IRTC Stock Comparison: AI Score, Valuation, Performance and Upside
EDAP TMS and IRTC (iRhythm) are both innovative medical device companies in early-to-mid commercial stages addressing large unmet clinical needs — EDAP with HIFU for prostate cancer treatment and iRhythm with wearable cardiac monitoring patches. Both face reimbursement and adoption challenges typical of innovative medical technologies seeking to establish standard-of-care positions.
EDAP vs IRTC compares two innovative small-to-mid-cap medical device companies leveraging technology to create less invasive alternatives in established clinical areas — prostate cancer treatment and cardiac arrhythmia monitoring.
Live analysis · updated 6/20/2026
EDAP holds the edge across 3 of 5 key metrics in this comparison. EDAP leads on both 1-year return (+169.49%) and forward P/E (-7.32x vs 99.54x for IRTC), a relatively favorable combination of momentum and valuation. Analyst consensus implies meaningfully more upside for IRTC (+70.98%) than for EDAP (+35.03%).
Normalized 1Y performance
EDAP
IRTC
Recent returns
EDAP
IRTC
Analyst price targets & sentiment
EDAP · 3 analysts
Price target range
analyst low$3.00
analyst high$10.00
analyst mean$5.83
current price$4.77
+35.0% upside to analyst mean
IRTC · 14 analysts
STRONG BUYHOLDSTRONG SELL
Strong Buy (1.3/5.0)
Price target range
analyst low$147.00
analyst high$255.00
analyst mean$178.93
current price$104.65
+71.0% upside to analyst mean
Who should consider this stock?
EDAP may suit investors who:
- →Want exposure to HIFU prostate cancer treatment technology at an early commercial stage in the U.S. market
- →Believe reimbursement expansion will unlock significant HIFU adoption among the millions of men diagnosed with localized prostate cancer annually
- →Are comfortable with small-cap medical device execution risk and a longer commercial ramp timeline
IRTC may suit investors who:
- →Want the market-leading wearable cardiac patch company with proven clinical adoption and physician preference over traditional Holter monitors
- →Value iRhythm's AI-powered cardiac analytics platform as a scalable infrastructure for arrhythmia detection at scale
- →See atrial fibrillation detection as an expanding diagnostic need driven by aging populations and growing stroke prevention awareness
Performance & AI score
| Metric | EDAP | IRTC |
|---|---|---|
| AI score | 37.0 | 34.5 |
| AI rank | #1454 | #1701 |
| Latest close | $4.77 | $104.65 |
| 1M return | +14.66% | -8.07% |
| 6M return | +102.98% | -37.48% |
| 1Y return | +169.49% | -28.09% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | EDAP | IRTC |
|---|---|---|
| 1Y ago | $26.95K (+169.5%) started 2025-06-12 | $7.19K (-28.1%) started 2025-06-18 |
| 5Y ago | $7.03K (-29.7%) started 2021-06-14 | $16.12K (+61.2%) started 2021-06-18 |
| 10Y ago | $14.79K (+47.9%) started 2016-06-13 | $40.17K (+301.7%) started 2016-10-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | EDAP | IRTC |
|---|---|---|
| Market cap | $161.92M | $3.44B |
| Trailing P/E | N/A | N/A |
| Forward P/E | -7.32 | 99.54 |
| Price/Sales | 2.19 | 4.37 |
| EV/Revenue | 2.59 | 4.77 |
| Analyst target | $5.83 | $178.93 |
| Target upside | +35.03% | +70.98% |
Growth, profitability & risk
| Metric | EDAP | IRTC |
|---|---|---|
| Revenue growth | 13.90% | 25.70% |
| Earnings growth | N/A | N/A |
| EPS growth | N/A | N/A |
| FCF margin | -13.14% | +7.24% |
| Operating margin | N/A | N/A |
| Profit margin | -41.70% | -3.53% |
| ROIC proxy | -123.96% | -22.42% |
| Return on equity | -123.96% | -22.42% |
| Dividend yield | N/A | 0.00% |
| Beta | -0.10 | 1.28 |
| Debt/equity | 275.14 | 452.39 |
| Current ratio | 1.34 | 5.17 |
| Quick ratio | 0.94 | 4.79 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
EDAP max drawdown35.36%
IRTC max drawdown46.21%
EDAP max wkly drop23.63%
IRTC max wkly drop15.97%
5Y risk snapshot
EDAP max drawdown90.03%
IRTC max drawdown66.03%
EDAP max wkly drop41.55%
IRTC max wkly drop25.00%
10Y risk snapshot
EDAP max drawdown90.03%
IRTC max drawdown84.39%
EDAP max wkly drop41.55%
IRTC max wkly drop41.32%
Performance metrics by period
| Period | Metric | EDAP | IRTC |
|---|---|---|---|
| 1Y | Growth | +169.49% | -28.09% |
| CAGR | +169.67% | -28.11% | |
| Sharpe ratio | 1.52 | -0.65 | |
| Max drawdown | 35.36% | 46.21% | |
| Max daily drop | 22.58% | 8.02% | |
| Max wkly drop | 23.63% | 15.97% | |
| 5Y | Growth | -29.75% | +61.22% |
| CAGR | -6.83% | +10.02% | |
| Sharpe ratio | 0.13 | 0.37 | |
| Max drawdown | 90.03% | 66.03% | |
| Max daily drop | 26.94% | 14.80% | |
| Max wkly drop | 41.55% | 25.00% | |
| 10Y | Growth | +47.91% | +301.73% |
| CAGR | +3.99% | +15.48% | |
| Sharpe ratio | 0.30 | 0.46 | |
| Max drawdown | 90.03% | 84.39% | |
| Max daily drop | 26.94% | 39.47% | |
| Max wkly drop | 41.55% | 41.32% |
Business comparison
| Category | EDAP | IRTC |
|---|---|---|
| Company | EDAP TMS S.A. | iRhythm Technologies, Inc. |
| Sector | Health Care - Medical Devices | Health Care - Medical Devices |
| Industry | N/A | N/A |
| Core business | EDAP TMS develops and markets high-intensity focused ultrasound (HIFU) systems for prostate cancer treatment, with its Focal One system providing a non-invasive alternative to surgery and radiation for localized prostate cancer, along with extracorporeal lithotripsy devices for kidney stone treatment. | iRhythm Technologies makes the Zio patch, a long-term wearable cardiac monitoring device that patients wear for up to two weeks to detect arrhythmias (particularly atrial fibrillation), replacing traditional bulky Holter monitors with a comfortable, water-resistant patch and AI-powered ECG analysis. |
| Investor focus | Investors track EDAP's Focal One HIFU system placements in the U.S. and Europe, procedure volume growth, U.S. reimbursement coverage expansion for HIFU prostate cancer treatment, and the company's clinical evidence development to support broader adoption. | Investors track iRhythm's Zio patch service volumes, revenue per patch, U.S. and international expansion, CMS reimbursement rate evolution, and the path to profitability as revenue scales over fixed infrastructure costs. |
EDAP strengths
- →HIFU provides a non-invasive alternative to prostatectomy or radiation therapy for localized prostate cancer, with lower side effect profiles that appeal to patients
- →Focal One is the only CE-marked and FDA-cleared robotic HIFU system for prostate cancer, establishing regulatory first-mover advantage
- →Prostate cancer is one of the most common cancers in men — the addressable patient population is very large if HIFU gains broader adoption and reimbursement
IRTC strengths
- →Zio patch is the market-leading wearable cardiac monitor with superior clinical evidence, physician satisfaction, and patient compliance versus traditional Holter monitors
- →AI-powered ECG analysis platform efficiently processes large volumes of cardiac data, providing cardiologists with actionable arrhythmia reports
- →Atrial fibrillation detection is critical — AF significantly increases stroke risk, and earlier detection enables preventive anticoagulation treatment
Risks to watch — EDAP
- →U.S. Medicare reimbursement for HIFU prostate cancer treatment has been limited, creating a significant adoption barrier for many patients
- →Urologist adoption requires physician education and patient referral pathway changes to compete with established surgery and radiation protocols
- →EDAP is a small-cap company with limited resources for commercial scale-up and clinical evidence development relative to large medical device competitors
Risks to watch — IRTC
- →CMS reimbursement rate changes create revenue per patch volatility — iRhythm has faced significant rate pressure in prior years
- →Competition from Bardy Diagnostics (acquired by Hillrom/Baxter), BioTelemetry (acquired by Philips), and CardioNet creates pricing pressure in the cardiac monitoring market
- →Path to profitability requires revenue growth to outpace the expensive service infrastructure (ECG analysis staffing and AI platform) supporting patch volume
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →